Quick Takeaways
- David R. Epstein has 8 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,460,508.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of David R. Epstein
- Location
- New York, NY
- Summary
- The estimated net worth of David R. Epstein is at least $1,460,508 dollars as of 18 Mar 2026. David R. Epstein is the Director of Tempus AI, Inc. and owns shares of Tempus AI, Inc. (TEM) stock worth about $1.31M. David R. Epstein is the Director of Axcella Health Inc. and owns shares of Axcella Health Inc. stock worth about $121.7K. David R. Epstein is the Director of Evelo Biosciences, Inc. and owns shares of Evelo Biosciences, Inc. (EVLO) stock worth about $31K.
- Signature
- /s/ Ellen Lefever, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow David R. Epstein and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Tempus AI, Inc. ($1,307,852).
- Past-year value change for that position: -$159,256.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of David R. Epstein
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| TEM | Tempus AI, Inc. | Director | $1,307,852 | -$159,256 | -11% | 02 Mar 2026 |
| AXLA | Axcella Health Inc. | Director | $121,658 | 19 May 2022 | ||
| EVLO | Evelo Biosciences, Inc. | Director | $30,998 | 30 Jun 2022 | ||
| AGMB | Agomab Therapeutics NV | Director | 18 Mar 2026 | |||
| OHAA | Opy Acquisition Corp. I | Director | 26 Oct 2021 | |||
| RUBY | Rubius Therapeutics, Inc. | Director | 12 May 2022 | |||
| SGEN | Seagen Inc. | CEO, Director | 14 Dec 2023 | |||
| SNTI | Senti Biosciences, Inc. | Director | 13 Jul 2022 |
Insider Transactions Reported by David R. Epstein:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.